Literature DB >> 26848606

Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor.

Mark Safe1, Andrew J Gifford2,3, Adam Jaffe1,3, Chee Yee Ooi1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26848606     DOI： 10.1513/AnnalsATS.201510-669LE

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  5 in total

Review 1.  The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.

Authors:  Millie Garg; Chee Y Ooi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

Review 2.  The CF gastrointestinal microbiome: Structure and clinical impact.

Authors:  Geraint B Rogers; Michael R Narkewicz; Lucas R Hoffman
Journal:  Pediatr Pulmonol       Date:  2016-10

3.  Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation.

Authors:  Chee Y Ooi; Saad A Syed; Laura Rossi; Millie Garg; Bronwen Needham; Julie Avolio; Kelsey Young; Michael G Surette; Tanja Gonska
Journal:  Sci Rep       Date:  2018-12-13       Impact factor: 4.379

Review 4.  Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.

Authors:  Rachel Y Tam; Josie M van Dorst; Isabelle McKay; Michael Coffey; Chee Y Ooi
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

5.  CFTR dysregulation drives active selection of the gut microbiome.

Authors:  Stacey M Meeker; Kevin S Mears; Naseer Sangwan; Mitchell J Brittnacher; Eli J Weiss; Piper M Treuting; Nicholas Tolley; Christopher E Pope; Kyle R Hager; Anh T Vo; Jisun Paik; Charles W Frevert; Hillary S Hayden; Lucas R Hoffman; Samuel I Miller; Adeline M Hajjar
Journal:  PLoS Pathog       Date:  2020-01-21       Impact factor: 6.823
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.